Dr. Rory Fisher, a professor in the Departments of Pharmacology and Internal Medicine, has renewed an R01 grant entitled: "Molecular Analysis and Role of RGS6 as a Novel Growth Suppressor" for 5 years beginning in April 2012. This project seeks to elucidate the role of RGS6 in suppression of tumorigenesis and the underlying mechanisms involved as well as the molecular basis for loss of RGS6 in human cancer. This award will fund pre-doctoral, post-doctoral and research scientists in his laboratory, and will build upon exciting research findings made by Professor Fisher revealing that RGS6 is both a tumor suppressor and an essential mediator of cancer cell death induced by the widely used chemotherapeutic agent doxorubicin. Curt D. Sigmund, Head of the Department of Pharmacology, said that Dr. Fisher is an imaginative, energetic and careful scientist whose research has tremendous potential to improve cancer chemotherapy. Collaborators on the project includes: Drs. Dawn Quelle (Pharmacology) and Ryan Askeland (Pathology).